Early pancreas transplant outcomes with histidine-tryptophan-ketoglutarate preservation: A multicenter study

Michael J. Englesbe, Alice Moyer, Dean Y. Kim, Darla K. Granger, Richard Pietroski, Atsushi Yoshida, Juan D. Arenas, Henry Oh, Shawn J. Pelletier, Darrell A. Campbell, Jeffrey D. Punch, John C. Magee, Scott A. Gruber, Randall S. Sung

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Little is known about the use of histidine-tryptophan-ketoglutarate (HTK) preservation solution for pancreas preservation. We compared early pancreas graft outcomes at four pancreas transplant programs within the state of Michigan in 2002 and 2003 (University of Wisconsin [UW] era) with those in 2004 (HTK era). The primary endpoint was early graft loss. The UW group (n=41) and the HTK group (n=36) had similar outcomes with respect to: technical graft loss (9.8% vs. 8.3%, P=NS), 90-day graft function (90.2% vs. 86.1%, P=NS), and rate of pancreatic leak/abscess (12.2% vs. 11.1%, P=NS). There were also no significant differences in postoperative amylase and lipase levels between the two groups. The HTK group did have significantly more acute rejection within the first 180 days (25.0% vs. 9.8%, P<0.05). HTK is a suitable substitute for UW in the preservation of pancreas allografts.

Original languageEnglish (US)
Pages (from-to)136-139
Number of pages4
Issue number1
StatePublished - Jul 1 2006


  • Clinical transplantation
  • Complications of clinical transplantation
  • Histidine-tryptophan-ketoglutarate (HTK)
  • Organ preservation
  • Pancreas
  • Surgical

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Early pancreas transplant outcomes with histidine-tryptophan-ketoglutarate preservation: A multicenter study'. Together they form a unique fingerprint.

Cite this